Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Little Urban areas to Visit in Western Europe - 2Sintana Energy flags major resource upgrade at Namibia oil discovery
- 3Japanese H3 rocket fails during launch of navigation satellite (video)
- 4Historic underwater structure discovered by divers off French coast
- 5Step by step instructions to Keep up with Great Hand Cleanliness Before Handshakes
- Man Charged for Stealing ‘Incredibly Precious’ 286-Year-Old Violin, Worth More Than $200,000, from a Tavern
- A Manual for Nations to Head out To
- World’s tallest bridge and biggest museum named ‘greatest places of 2026’
- Which camera do you believe is great for first-time clients? !
- Timex Gives Its Classic Affordable Field Watch a Tactical, Milspec Makeover
- A definitive Manual for Choosing Indoor Plants Ideal for Your Space
- What's Your Number one Superhuman Film Made?
- Plans for ‘stop anywhere’ night buses recommended by government for women’s safety
- How the Iran war may affect your money and bills
